• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对卵巢癌腹膜癌病的间皮素靶向 CAR.CIK 淋巴细胞的三维动力学。

Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis.

机构信息

Department of Oncology, University of Torino, Turin, Italy.

Candiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy.

出版信息

Cancer Immunol Immunother. 2024 Nov 2;74(1):6. doi: 10.1007/s00262-024-03860-w.

DOI:10.1007/s00262-024-03860-w
PMID:39487859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11531451/
Abstract

Intraperitoneal cellular immunotherapy with CAR-redirected lymphocytes is an intriguing approach to target peritoneal carcinomatosis (PC) from ovarian cancer (OC), which is currently evaluated in clinical trials. PC displays a composite structure with floating tumor cells within ascites and solid-like masses invading the peritoneum. Therefore, a comprehensive experimental model is crucial to optimize CAR-cell therapies in such a peculiar environment. Here, we explored the activity of cytokine-induced killer lymphocytes (CIK), redirected by CAR against mesothelin (MSLN-CAR.CIK), within reductionistic 3D models resembling the structural complexity of both liquid and solid components of PC. MSLN-CAR.CIK effectively killed and were functionally efficient against OC targets. In a "floating-like" 3D context with floating OC spheroids, both tumor localization and killing by MSLN-CAR.CIK were significantly boosted by fluid flow. In a "solid-like" context, MSLN-CAR.CIK were recruited through the extracellular matrix on embedded tumor aggregates, with variable kinetics depending on the effector-target distance. Furthermore, MSLN-CAR.CIK penetrated the inner levels of OC spheroids exerting effective tumor killing. Our findings provide currently unknown therapeutically relevant information on intraperitoneal approaches with CAR.CIK, supporting further developments and improvements for clinical studies in the context of locoregional cell therapy approaches for patients with PC from OC.

摘要

腹腔内细胞免疫疗法联合 CAR 修饰的淋巴细胞是一种很有前途的治疗卵巢癌腹膜转移(PC)的方法,目前正在临床试验中进行评估。PC 表现为一种复合结构,其中腹水内有漂浮的肿瘤细胞,而实性肿块则侵袭腹膜。因此,建立一个全面的实验模型对于优化这种特殊环境下的 CAR 细胞治疗至关重要。在这里,我们研究了 CAR 修饰的细胞因子诱导的杀伤细胞(CIK)在简化的 3D 模型中的活性,该模型模拟了 PC 液体和固体成分的结构复杂性。MSLN-CAR.CIK 有效地杀伤 OC 靶细胞,并且具有功能性。在具有漂浮 OC 球体的“漂浮样”3D 环境中,MSLN-CAR.CIK 的肿瘤定位和杀伤能力均显著增强。在“实体样”环境中,MSLN-CAR.CIK 通过细胞外基质募集到嵌入的肿瘤聚集体上,其动力学取决于效应细胞-靶细胞的距离。此外,MSLN-CAR.CIK 还能穿透 OC 球体的内部,发挥有效的肿瘤杀伤作用。我们的研究结果提供了关于 CAR.CIK 腹腔内治疗方法的目前未知的治疗相关信息,为局部区域细胞治疗方法治疗 OC 患者 PC 的临床研究提供了进一步的发展和改进的支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/f702af23da09/262_2024_3860_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/dda331bd6046/262_2024_3860_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/512863297c1d/262_2024_3860_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/06b3f8610f81/262_2024_3860_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/aa2a24e095c7/262_2024_3860_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/f702af23da09/262_2024_3860_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/dda331bd6046/262_2024_3860_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/512863297c1d/262_2024_3860_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/06b3f8610f81/262_2024_3860_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/aa2a24e095c7/262_2024_3860_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2280/11531451/f702af23da09/262_2024_3860_Fig5_HTML.jpg

相似文献

1
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis.针对卵巢癌腹膜癌病的间皮素靶向 CAR.CIK 淋巴细胞的三维动力学。
Cancer Immunol Immunother. 2024 Nov 2;74(1):6. doi: 10.1007/s00262-024-03860-w.
2
Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.嵌合抗原受体 NK-92 细胞在卵巢癌中针对间皮素的应用。
Biochem Biophys Res Commun. 2020 Mar 26;524(1):96-102. doi: 10.1016/j.bbrc.2020.01.053. Epub 2020 Jan 22.
3
Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study.新型多链 DAP-CAR-T 细胞靶向间皮素治疗卵巢癌和间皮瘤的疗效和安全性:一项单臂、开放标签、首例人体研究。
Genome Med. 2024 Nov 15;16(1):133. doi: 10.1186/s13073-024-01405-5.
4
Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals.源自人类胚胎干细胞的间皮素嵌合抗原受体工程化自然杀伤细胞可抑制动物体内人类卵巢癌的进展。
Cell Prolif. 2024 Dec;57(12):e13727. doi: 10.1111/cpr.13727. Epub 2024 Aug 13.
5
Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.重新利用抗间皮素嵌合抗原受体自然杀伤细胞免疫疗法治疗结直肠癌。
J Transl Med. 2024 Dec 4;22(1):1100. doi: 10.1186/s12967-024-05851-y.
6
Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells.氟达拉滨和三氧化二砷对卵巢肿瘤细胞和间皮素嵌合抗原受体 T 细胞的影响。
Cancer Immunol Immunother. 2024 Jul 2;73(9):163. doi: 10.1007/s00262-024-03740-3.
7
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.CAR 记忆样 NK 细胞靶向间皮素的膜近端结构域,在卵巢癌中表现出有前景的活性。
Sci Adv. 2024 Jul 12;10(28):eadn0881. doi: 10.1126/sciadv.adn0881.
8
Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.腺苷 2A 受体的破坏可提高抗间皮素 CAR T 细胞的抗肿瘤功能,无论是在体外还是体内。
Exp Cell Res. 2021 Dec 1;409(1):112886. doi: 10.1016/j.yexcr.2021.112886. Epub 2021 Oct 19.
9
Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.抗人间皮素靶向嵌合抗原受体信使 RNA 转染外周血淋巴细胞治疗卵巢癌的研究进展。
Hum Gene Ther. 2018 May;29(5):614-625. doi: 10.1089/hum.2017.080. Epub 2018 Apr 2.
10
Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.显性负性转化生长因子-β受体装甲间皮素靶向嵌合抗原受体 T 细胞在卵巢癌小鼠模型中减缓肿瘤生长。
Cancer Immunol Immunother. 2023 Apr;72(4):917-928. doi: 10.1007/s00262-022-03290-6. Epub 2022 Sep 27.

引用本文的文献

1
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors.从球体到类器官:实体瘤中CAR-T细胞疗法研究的下一代模型
Front Immunol. 2025 Jul 11;16:1626369. doi: 10.3389/fimmu.2025.1626369. eCollection 2025.

本文引用的文献

1
Neoantigen cancer vaccines: a new star on the horizon.新抗原癌症疫苗:崭露头角的新星。
Cancer Biol Med. 2023 Dec 29;21(4):274-311. doi: 10.20892/j.issn.2095-3941.2023.0395.
2
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.CSPG4 CAR-redirected 细胞因子诱导的杀伤细胞(CIK)作为 HLA Ⅰ类缺陷型黑色素瘤有效的细胞免疫治疗。
J Exp Clin Cancer Res. 2023 Nov 22;42(1):310. doi: 10.1186/s13046-023-02884-x.
3
Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production.
抗原呈递细胞和嵌合抗原受体T细胞的相互激活通过持续高水平产生干扰素γ引发广泛的内源性抗肿瘤免疫反应。
Cancer Biol Med. 2023 Nov 6;20(11):779-82. doi: 10.20892/j.issn.2095-3941.2023.0324.
4
The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer.诱导型分泌 TLR5 激动剂 CBLB502 增强 CAR133-NK92 细胞在结直肠癌中的抗肿瘤活性。
Cancer Biol Med. 2023 Sep 19;20(9):662-81. doi: 10.20892/j.issn.2095-3941.2023.0033.
5
Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites.电解质失衡导致恶性腹水 NK 和 T 细胞效应功能受抑制。
J Exp Clin Cancer Res. 2023 Sep 8;42(1):235. doi: 10.1186/s13046-023-02798-8.
6
How can Cytokine-induced killer cells overcome CAR-T cell limits.细胞因子诱导的杀伤细胞如何克服 CAR-T 细胞的局限性。
Front Immunol. 2023 Aug 22;14:1229540. doi: 10.3389/fimmu.2023.1229540. eCollection 2023.
7
Immune checkpoint inhibitors in ovarian cancer: where do we go from here?卵巢癌中的免疫检查点抑制剂:我们从这里走向何方?
Cancer Drug Resist. 2023 Jun 14;6(2):358-377. doi: 10.20517/cdr.2023.13. eCollection 2023.
8
Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer.局部化疗方法与先进药物递送策略:卵巢癌腹膜癌治疗的新进展。
Front Oncol. 2023 May 23;13:1125868. doi: 10.3389/fonc.2023.1125868. eCollection 2023.
9
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.单次 CAR-T 细胞治疗可控制同种异体小鼠模型中的播散性卵巢癌。
J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2022-006509.
10
Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models.MSLN-CAR T 细胞的靶向激活可诱导卵巢癌模型产生更优的抗肿瘤反应。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005691.